tradingkey.logo
tradingkey.logo
Search

Hungary's Richter and Hikma receive FDA approval for denosumab biosimilars

ReutersSep 29, 2025 6:13 AM
facebooktwitterlinkedin
View all comments0

- Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says in a statement:

  • RICHTER AND HIKMA RECEIVE FDA APPROVAL FOR DENOSUMAB BIOSIMILARS ENOBYTM AND XTRENBO, REFERENCING PROLIA AND XGEVA, RESPECTIVELY

  • UNDER THE TERMS OF THE AGREEMENT RICHTER IS RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURE OF THE PRODUCTS

  • HIKMA IS RESPONSIBLE FOR THE FDA REGISTRATION AND EXCLUSIVE COMMERCIALIZATION IN THE U.S.

  • DENOSUMAB IS INDICATED FOR TREATING OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Source text: [https://www.bse.hu/newkibdata/129324268/Denosumab_FDA_Approval_Sep2025_EN.pdf]

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI